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Abstract 
 
Purpose:  A study was made of the effects of some bases and adjuvants on the physical and release 
properties of metronidazole suppositories with a view to providing more information for the optimization 
of the rectal formulation of metronidazole. 
Method:   Suppositories (1g) containing 200mg of metronidazole each were prepared in witepsol (H15 
and E75) and polyethylene glycol (PEG 2850 and 4650) bases, using different concentrations of Tween 
80, sodium salicylate and methylcellulose as adjuvants. The setting time, solidification point and melting 
range of the suppositories were determined, along with their crushing strength, disintegration time and 
the time for 80% of metronidazole to be released from the suppositories (t80). 
Results:    The ranking of setting time for the suppositories was witepsol H15 > PEG 2850 > witepsol 
E75 > PEG 4650, while the ranking of solidification point, melting range, crushing strength, 
disintegration time and the time for 80% of metronidazole to be released from the suppositories (t80) was 
the reverse of that for setting time. Optimal concentrations of Tween 80 and sodium salicylate were 
observed for the suppository formulations. Using Kitazawa plots, all formulations showed two dissolution 
rate constants, k1 and k2 intersecting at time t1, with formulations containing 5 to 20 % w/w of 
methylcellulose exhibiting a third dissolution rate constant, k3 intersecting with k2 at time t2.  
Conclusion:  The physical and release properties of metronidazole suppositories are influenced 
considerably by the bases and adjuvants employed. Tween 80 and sodium salicylate can probably be 
used to formulate only immediate-release suppositories while methylcellulose can be useful for 
sustained-release metronidazole suppositories. Some insight into these inferences can be obtained from 
parameters derived from Kitazawa plots.  
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INTRODUCTION 
 
Suppositories have been recognized as an 
alternative to the oral route in situations such 
as when the patient is comatose, unable to 
swallow or when the drug produces nausea or 
vomiting. In the light of this, efforts have been 
made in recent times to present a good 
number of drugs in suppository form1,2,3,4. 
However, investigators have shown that the 
physical and release properties of many 
suppositories depend considerably on the 
physicochemical properties of the drug, 
suppository base and formulation 
adjuvants1,5,6 and a lot of formulation work is 
therefore normally required to optimise the 
properties of suppository preparations. 
 
In the case of metronidazole, which has also 
been presented in suppository form2,7,8,9 due 
to various factors, especially gastrointestinal 
disturbances and nausea when given orally6,7, 
there have been reports of a lot of variability in 
drug release from different suppository 
formulations2,7.  
 
Thus, the present work was designed to 
investigate the effects of some formulation 
factors on the physical and release properties 
of metronidazole suppositories with a view to 
providing more information on the way to 
optimize the properties of the resulting 
suppositories. It was considered of interest to 
study the effects of different formulation 
adjuvants with different properties on the 
physical and release properties of 
metronidazole in witepsol and polyethylene 
glycol (PEG) suppository formulations. 
 
MATERIALS AND METHODS 
Materials 
The materials used were metronidazole BP 
(Rhone Poulenc, France); Witepsol H15 and 
E75 (Huls AG, France); Polyethylene glycol, 
PEG 1500 and PEG 6000 (Merck, Germany); 
Tween 80 and sodium salicylate (Merck, 
Germany); and methylcellulose (Bufa B.V., 
Netherlands). 
 
 
 
Preparation of suppositories 
Suppositories (1g) containing 200mg of 
metronidazole each were prepared by the 
fusion method following a previously 
described method2 using Witepsol H15, 
Witepsol E75, and  blends of polyethylene 
glycol 1500 and 6000 (70%:30% and 
30%:70%) to give PEG 2850 and PEG 4650, 
respectively. The appropriate quantity of each 
suppository base was melted on a water bath. 
Prior to incorporation, metronidazole powder 
was passed through a 100 µm mesh sieve. 
Sodium salicylate was micronised and also 
passed through the same sieve. Quantities 
corresponding to 200mg of the metronidazole 
powder with and without adjuvant were added 
with trituration, using displacement value 
calculations.  Adjuvants (Tween 80, sodium 
salicylate or methylcellulose) were added in 
different concentrations of 1, 3, 5 or 10% w/w 
for Tween 80 or sodium salicylate, and 1,5,10 
or 20% w/w for methylcellulose. Mixing was 
continued until a homogeneous mass was 
produced. The mass was poured into 
stainless steel moulds, allowed to cool and the 
suppositories removed. Suppositories were 
weighed and kept at room temperature for 24h 
after removal from the mould to allow for 
uniform solidification and crystal 
transformation. The prepared suppositories 
were wrapped in aluminium foil and stored in 
a dessicator in a refrigerator until needed. 
 
Evaluation of physical properties of 
suppositories 
The prepared suppositories were subjected to 
several physical tests. The ease of moulding 
of the suppositories was assessed by the 
setting time of the molten mass, which was 
taken as the time for the suppository to set in 
the mould10. 
 
Solidification point was also determined10. The 
test suppository was melted in a test tube at 
450C. A thermometer was dipped inside the 
cooling mass and rotated mechanically. The 
temperature at which the mass first began to 
adhere to the thermometer was recorded as 
the solidification point10. 
Itiola & Adegboye 
Trop J Pharm Res March 2008; 7 (1) 889
Melting range was determined using the 
ascending melting point method10. 
Suppositories to be tested were melted in a 
water bath. One end of a straight capillary 
tube was dipped into the molten mass. The 
molten mass was allowed to rise to 5cm in the 
capillary tube and stored for 24h in the 
refrigerator. The capillary tube was then 
attached to a thermometer graduated in 0.20 
increments and lowered into a water bath 
heated so that the temperature rose at the 
rate of 10C per minute. The temperature at 
which the suppository began to melt and the 
temperature when clarification was observed 
were recorded as a range for the melting 
point. 
 
The prepared suppositories were evaluated 
for uniformity of weight using twenty (20) 
suppositories for each formulation in 
accordance with the BP method11. Content 
uniformity was determined by 
spectrophotometric method. The suppositories 
were individually melted and dissolved in 
100ml of phosphate buffer. After dilution, the 
absorbance was measured on a 
spectrophotometer (Pye Unicam, SP 6-550, 
Cambridge, England) at a wavelength of 
275nm. It was established in preliminary 
experiments that the suppository bases and 
other materials did not interfere with 
absorbance measurement of metronidazole. 
The Erweka breaking strength tester (Erweka 
Apparatebau GmbH, Germany) was used to 
measure the resistance of the suppositories to 
crushing. All determinations were done in 
quadruplicate.   
  
Evaluation of disintegration and release 
properties of the suppositories 
Disintegration time of the suppositories was 
determined2. The suppository to be tested 
was placed in a special glass container with 
perforated ends and immersed in a water bath 
maintained at 37 ± 10C. A magnetic stirrer set 
at 100rpm was placed in the glass container. 
The time for disintegration was noted when 
the suppository has completely melted 
(Witepsol) or dissolved (PEG) in the medium. 
In vitro release tests were carried out 
according to the USP XX basket method using 
the Hanson Easi-Lift dissolution equipment. 
Each suppository was placed in the basket12 
and lowered into a flask containing 500ml of 
phosphate buffer solution, pH 7.2, maintained 
at a constant temperature (37 ± 0.50C). The 
basket was rotated at a constant speed of 
50rpm. Samples (5 ml) were withdrawn at 
specified time intervals. Fresh buffer solution 
maintained at experimental temperature was 
used to replace the same volume of 
withdrawn samples.The amount of 
metronidazole in each sample was analysed 
spectophotometrically at 275nm (Pye Unicam, 
SP 6-550, Cambridge, England). The mean of 
four determinations was used to calculate 
drug release from each of the formulation.  
 The integrated form of the equation of 
Noyes and Whitney13, which has found wide 
application in describing the release kinetics 
of drugs from tablet dosage forms14, 15, 16 is 
given below: 
  
ln[Cs/(Cs-C) ]        =        kt                        (1)    
Where Cs is the concentration of the solute at 
saturation, C is its concentration at time t, and 
k is a dissolution rate constant. Adegboye and 
Itiola2 have found this equation applicable to 
the release kinetics of suppository 
formulations. Kitazawa plots of ln[Cs/(Cs-C) ] 
versus t were constructed for all 
formulations14. 
 
Statistical analysis 
Results are expressed as the mean ± SD of 
four determinations. Analysis of variance 
(ANOVA) was used to test the statistical 
significance of differences among groups. 
 
RESULTS  
The results of all physical tests are presented 
in Table 1. The results show that all prepared 
suppositories satisfied the BP requirement11 
for weight uniformity, with none of the 
individual weights deviating from the average 
by more than 5%. Also, the mean drug 
content for the suppositories was found to 
satisfy the BP requirement11 for content 
uniformity for most suppository formulations. 
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None of the suppository formulations had less 
than 90% and none had more than 110% of 
expected metronidazole content. 
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Figure 1: Plots of disintegration time against concentration   Figure 2: Plots of release profiles of  
of adjuvant for witepsol H15 formulations containing different  metronidazole from witepsol E75 
adjuvants. ○– Tween 80; ■ – sodium salicylate;    containing 5%w/w of the different  
▲ – methylcellulose   adjuvants. ○ – blank; ▲ – Tween 80; ■ –  
   sodium salicylate; □– methylcellulose. 
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Figure 3: Kitazawa plots of release of metronidazole from PEG 4650 formulations 
containing 5%w/w of the different adjuvants. ∆- blank; ■- Tween 80;▲- sodium salicylate; □- 
methylcellulose. 
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Table 1: Physicochemical properties of  metronidazole suppositories 
 
 
Base Adjuvant Conc. 
of 
adjuvan
t 
Setting 
time (min) 
S(SD) 
Weight(g) 
 
X(SD) 
Drug 
content 
%(SD) 
Solidificatio
n point 
0C(SD) 
Melting 
range0C 
Crushin
g 
strength 
N (SD) 
- 0.0 17.50(0.12) 1.010(0.020) 98.4(2.4) 30.0(0.4) 33.5-
35.0 
14.7(1.0) 
Tween 80 1.0 
3.0 
5.0 
10.0 
17.15(0.24) 
14.80(1.44) 
14.00(1.12) 
13.55(1.32) 
1.014(0.040) 
1.018(0.080) 
1.025(0.024) 
1.040(0.050) 
96.2(1.8) 
96.9(1.5) 
98.4(0.8) 
98.2(2.3) 
30.0(1.9) 
29.5(2.2) 
29.0(1.9) 
28.5(0.5) 
33.5-
35.0 
32.5-
34.0 
31.5-
32.5 
30.0-
31.5 
15.1(1.6) 
15.7(2.7) 
16.7(2.1) 
16.9(1.4) 
Sodium 
salicylate 
1.0 
3.0 
5.0 
10.0 
15.00(0.24) 
13.86(1.44) 
9.60(1.12) 
8.50(1.32) 
1.011(0.034) 
1.014(0.018) 
1.019(0.024) 
1.028(0.015) 
96.2(1.8) 
96.9(1.5) 
98.4(0.8) 
98.2(2.3) 
32.0(1.9) 
32.5(2.2) 
33.5(0.9) 
34.5(1.5) 
33.5-
35.5 
33.5-
36.0 
33.5-
36.5 
33.5-
37.0 
16.7(1.3) 
19.6(2.4) 
21.5(0.1) 
22.2(1.2) 
Witepso
l H15 
Methylcellulose 1.0 
5.0 
10.0 
20.0 
13.50(0.24) 
10.10(1.44) 
6.40(1.12) 
5.80(1.32) 
1.019(0.017) 
1.024(0.080) 
1.033(0.024) 
1.056(0.005) 
96.2(1.8) 
96.9(1.5) 
98.4(0.8) 
98.2(2.3) 
32.5(1.9) 
33.0(1.3) 
34.5(1.8) 
35.5(1.6) 
33.5-
36.0 
34.0-
36.0 
34.5-
37.0 
35.0-
38.0 
18.6(1.0) 
24.9(2.7) 
28.4(2.1) 
32.0(0.8) 
         
- 0.0 10.55(0.12) 1.060(0.020) 97.6(1.3) 34.0(1.1) 36.5-
38.0 
21.6(2.0) 
Tween 80 1.0 
3.0 
5.0 
10.0 
10.00(0.24) 
8.50(1.44) 
7.75(1.12) 
7.20(1.32) 
1.066(0.045) 
1.070(0.037) 
1.077(0.024) 
1.080(0.019) 
96.2(1.8) 
96.9(1.5) 
98.4(0.8) 
98.2(2.3) 
34.0(2.7) 
33.5(1.1) 
33.0(1.4) 
32.5(1.2) 
36.5-
38.0 
36.0-
37.0 
35.0-
36.0 
34.5-
35.0 
22.7(2.2) 
25.5(2.3) 
26.3(0.9) 
27.4(1.0) 
Sodium 
salicylate 
1.0 
3.0 
5.0 
10.0 
9.00(0.24) 
8.10(1.44) 
6.00(1.12) 
5.40(1.32) 
1.062(0.012) 
1.065(0.016) 
1.069(0.028) 
1.075(0.031) 
96.2(1.8) 
96.9(1.5) 
98.4(0.8) 
98.2(2.3) 
35.5(1.8) 
36.5(0.9) 
37.0(1.1) 
38.0(1.1) 
36.5-
38.5 
36.5-
39.0 
36.5-
39.5 
36.5-
40.0 
28.0(1.4) 
30.8(2.3) 
31.6(1.7) 
32.5(0.4) 
Witepso
l E75 
Methylcellulose 1.0 
5.0 
10.0 
20.0 
7.00(0.24) 
5.80(1.44) 
4.40(1.12) 
3.00(1.32) 
1.071(0.019) 
1.078(0.027) 
1.085(0.025) 
1.096(0.005) 
96.2(1.8) 
96.9(1.5) 
98.4(0.8) 
98.2(2.3) 
36.0(1.3) 
37.0(1.2) 
37.5(1.7) 
38.5(0.5) 
37.0-
38.5 
37.5-
39.0 
37.5-
39.5 
38.0-
40.0 
29.4(0.1) 
34.5(0.6) 
37.2(1.6) 
41.1(0.9) 
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- 0.0 14.70(0.12) 1.040(0.020) 98.4(2.4) 31.0(0.4) 35.0-
37.0 
17.6(0.5) 
Tween 80 1.0 
3.0 
5.0 
10.0 
14.00(0.24) 
12.90(1.44) 
11.00(1.12) 
10.50(1.32) 
1.045(0.240) 
1.048(0.180) 
1.054(0.024) 
1.060(0.005) 
96.2(1.8) 
96.9(1.5) 
98.4(0.8) 
98.2(2.3) 
31.5(1.9) 
31.5(1.2) 
32.0(1.6) 
32.5(1.5) 
35.0-
37.0 
34.5-
36.0 
34.0-
35.5 
33.5-
35.0 
18.6(0.7) 
20.5(1.6) 
22.5(1.4) 
25.4(1.2) 
Sodium 
salicylate 
1.0 
3.0 
5.0 
10.0 
12.00(0.24) 
6.42(1.44) 
6.00(1.12) 
5.20(1.32) 
1.041(0.240) 
1.043(0.180) 
1.046(0.024) 
1.050(0.005 
96.2(1.8) 
96.9(1.5) 
98.4(0.8) 
98.2(2.3) 
31.5(1.9) 
32.0(1.1) 
33.0(0.3) 
34.0(1.4) 
33.5-
36.5 
36.0-
37.5 
36.5-
38.0 
36.0-
38.5 
19.0(2.0) 
21.5(1.9) 
25.5(0.2) 
30.4(0.8) 
0PEG 
2850 
methylcellulos
e 
1.0 
5.0 
10.0 
20.0 
10.00(0.24) 
8.50(1.44) 
6.25(1.12) 
5.00(1.32) 
1.048(0.240) 
1.055(0.180) 
1.065(0.024) 
1.080(0.005 
96.2(1.8) 
96.9(1.5) 
98.4(0.8) 
98.2(2.3) 
32.0(1.3) 
33.5(1.2) 
34.0(1.5) 
35.0(1.5) 
35.5-
37.0 
36.5-
38.0 
37.0-
39.0 
37.5-
39.0 
21.6(0.6) 
25.5(2.2) 
29.4(1.1) 
37.2(1.0) 
         
- 0.0 7.40(0.12 1.090(0.020 97.6(1.3) 34.5(2.0) 38.0-
40.0 
24.5(0.1) 
Tween 80 1.0 
3.0 
5.0 
10.0 
7.20(0.24) 
6.00(1.44) 
4.80(1.12) 
4.10(1.32) 
1.093(0.240) 
1.097(0.180) 
1.099(0.024) 
1.103(0.005 
96.2(1.8) 
96.9(1.5) 
98.4(0.8) 
98.2(2.3) 
34.5(1.3) 
35.0(1.0) 
35.5(1.6) 
36.0(1.5) 
38.0-
39.5 
37.5-
39.0 
37.0-
38.5 
36.5-
38.0 
25.4(1.2) 
26.5(0.2) 
28.4(0.5) 
30.3(0.8) 
Sodium 
salicylate 
1.0 
3.0 
5.0 
10.0 
6.50(0.24) 
4.40(1.44) 
4.00(1.12) 
3.50(1.32) 
1.091(0.240) 
1.093(0.180) 
1.095(0.024) 
1.099(0.005 
96.2(1.8) 
96.9(1.5) 
98.4(0.8) 
98.2(2.3) 
35.0(1.0) 
35.5(1.2) 
36.0(0.1) 
37.0(2.5) 
38.0-
40.0 
38.0-
41.0 
38.0-
41.5 
38.0-
42.0 
26.5(2.5) 
27.5(0.7) 
29.4(1.3) 
33.3(0.9) 
PEG 
4650 
methylcellulos
e 
1.0 
5.0 
10.0 
20.0 
5.00(0.24) 
4.00(1.44) 
2.80(1.12) 
2.00(1.32) 
1.095(0.240) 
1.099(0.180) 
1.103(0.024) 
1.110(0.005) 
96.2(1.8) 
96.9(1.5) 
98.4(0.8) 
98.2(2.3) 
35.5(2.2) 
36.5(1.2) 
37.5(1.8) 
39.0(0.5) 
38.0-
40.5 
39.0-
41.0 
39.5-
41.5 
40.0-
42.0 
27.4(1.0) 
32.3(2.0) 
38.2(1.5) 
44.1(1.8) 
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From Table 1, it is also seen that the ranking 
of setting time, which indicates the ease of 
moulding, for the different bases was witepsol 
H15 > PEG 2850 > witepsol E75 > PEG 4650. 
It is notable however that the ranking of 
solidification point, melting range and crushing 
strength for the different bases was a reverse 
of the ranking for setting time: PEG 4650 > 
witepsol E75 > PEG 2850 > witepsol H15. 
Table 1 also shows that the adjuvants 
exhibited considerable effects on the different 
parameters. Setting time decreased with 
incorporation of all the adjuvants while 
crushing strength increased. On the other 
hand, values of melting range and 
solidification point were decreased by 
incorporation of Tween 80, but increased with 
methylcellulose and sodium salicylate. 
 
Figure 1 shows representative plots of 
disintegration time (DT) against concentration 
of adjuvant. Figure 2 shows representative 
release profiles of metronidazole from 
witepsol E75 containing 5%w/w of the different 
adjuvants. The time for 80% of metronidazole 
to be released (t80) was obtained for all 
formulations. The values of DT and t80 are 
presented in Table 2, and both parameters 
also show ranking for the different bases 
which was the reverse of that for setting time: 
PEG 4650 > witepsol E75 > PEG 2850 > 
witepsol H15. The values of DT and t80 
decreased with increasing concentration of 
Tween 80 and sodium salicylate, but 
increased with methylcellulose.  
 
Figure 3 shows representative Kitazawa plots 
of release of metronidazole from PEG 4650 
formulations containing 5% w/w of the different 
adjuvants. Two linear regression lines of 
slopes k1 and k2 intersecting at time t1 were 
obtained for all formulations, while an 
additional third regression line of slope k3 
intersecting at time t2 was obtained for 
formulations containing 5, 10 and 20% w/w 
methylcellulose. Values of all parameters 
derived from Kitazawa plots are included in 
Table 2. It is seen that the values of k1 and k2 
increased with increased in concentration of 
Tween 80 or sodium salicylate, but decreased 
with increase in concentration of 
methylcellulose. The values of k3 also 
decreased with increasing concentration of 
methylcellulose for the relevant suppository 
formulations. 
 
DISCUSSION   
The physical and release properties of 
metronidazole suppositories were studied to 
provide more insights into the ways of 
optimizing the rectal formulation of the drug. 
The results obtained indicate that the 
prepared suppositories met official standards 
with regard to weight and content uniformity 
as presented in Table 1. The results (Tables 1 
and 2) also show that the physical and release 
properties of the suppositories were affected 
considerably by the formulation variables 
employed. The rankings of most of the 
physical and release parameters for the 
different suppository bases show that the 
bases can probably be employed to formulate 
metronidazole suppository formulations with a 
variety of physical and release properties for 
different purposes. The rankings also suggest 
that the values of most of the parameters 
increased with the ease with which the 
suppositories were moulded in the different 
bases as measured by the setting time.   
 
The ranking of the dissolution rate constants 
was k1 < k2 < k3 for relevant formulations 
(Table 2), showing an increase in the rate of 
release of metronidazole with time. The t1 
values were found to decrease with increase 
in concentration of Tween 80 and sodium 
salicylate, but increased with increase in 
concentration of methylcellulose. The t2 
values (for formulations containing 5, 10 and 
20% w/w methylcellulose) also increased with 
increase in methylcellulose content.  Table 2 
also shows that for all formulations, time t1 
was generally greater than the disintegration 
time, DT. Thus the disintegration time for the 
formulations did not correspond with the time 
for the change from k1 to k2 at t1, but rather DT 
occurred before t1. While this may be 
attributed to the greater agitation associated 
with the disintegration test15, it may also 
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suggest that the melting/dissolving time of the 
suppository does not necessarily correspond  
 exactly to the time of a change in dissolution 
rate. 
Table 2: Release properties of  metronidazole suppositories 
  
Base Adjuvant Conc. of 
adjuvan
t 
DT 
 (min) 
t80 (min) k1 k2 k3  t1 
(min) 
t2 
(min) 
- 0.0 15.20(1.11) 23.60(0.56) 0.067 
 
0.081 - 
 
20 - 
Tween 80 1.0 
3.0 
5.0 
10.0 
14.42(1.56) 
7.85(1.48) 
7.53(2.36) 
7.41(2.56) 
16.58(1.21) 
11.15(0.04) 
10.90(1.71) 
10.82(0.84) 
0.090 
0.135 
0.137 
0.140 
0.210 
0.315 
0.333 
0.350 
- 
- 
- 
- 
15 
10 
10 
10 
- 
- 
- 
- 
Sodium 
salicylate 
1.0 
3.0 
5.0 
10.0 
15.00(1.56) 
14.80(1.48) 
10.15(2.36) 
9.56(2.56) 
22.80(0.22) 
22.00(0.90) 
16.45(1.06) 
16.24(0.34) 
0.069 
0.072 
0.093 
0.096 
0.104 
0.122 
0.206 
0.216 
- 
- 
- 
- 
20 
20 
15 
15 
- 
- 
- 
- 
Witepsol 
H15 
Methylcellulose 1.0 
5.0 
10.0 
20.0 
16.00(1.56) 
19.50(1.48) 
22.64(2.36) 
31.50(2.56) 
36.56(0.65) 
53.30(1.11) 
70.00(0.70) 
88.68(0.04) 
0.045 
0.030 
0.015 
0.007 
0.060 
0.042 
0.032 
0.021 
- 
0.066 
0.043 
0.035 
30 
45 
60 
75 
- 
75 
90 
150 
          
- 0.0 28.60(1.11) 53.65(0.54) 0.026 0.055 - 45 - 
Tween 80 1.0 
3.0 
5.0 
10.0 
27.00(1.56) 
20.65(1.48) 
19.44(2.36) 
19.25(2.56) 
37.90(0.78) 
24.40(1.12) 
24.00(0.92) 
23.70(1.40) 
0.040 
0.065 
0.067 
0.070 
0.060 
0.082 
0.085 
0.087 
- 
- 
- 
- 
30 
20 
20 
20 
- 
- 
- 
- 
Sodium 
salicylate 
1.0 
3.0 
5.0 
10.0 
28.00(1.56) 
27.48(1.48) 
20.72(2.36) 
19.58(2.56) 
50.55(1.36) 
48.68(1.78) 
34.00(0.06) 
33.80(0.50) 
0.030 
0.032 
0.045 
0.046 
0.057 
0.061 
0.076 
0.078 
- 
- 
- 
- 
45 
45 
30 
30 
- 
- 
- 
- 
Witepsol 
E75 
Methylcellulose 1.0 
5.0 
10.0 
20.0 
29.00(1.56) 
32.40(1.48) 
36.16(2.36) 
41.00(2.56) 
67.55(0.99) 
75.00(0.22) 
93.00(1.00) 
136.00(0.21) 
0.022 
0.020 
0.016 
0.013 
0.042 
0.027 
0.019 
0.008 
- 
0.053 
0.041 
0.028 
60 
60 
75 
90 
- 
75 
105 
180 
- 0.0 20.88(1.11) 38.55(0.88) 0.042 0.055 - 30 - PEG 
2850 Tween 80 1.0 
3.0 
5.0 
10.0 
19.25(1.56) 
15.82(1.48) 
12.56(2.36) 
13.98(2.56) 
34.68(0.58) 
24.00(0.96) 
23.35(1.24) 
25.36(0.95) 
0.046 
0.066 
0.069 
0.064 
0.062 
0.079 
0.082 
0.068 
- 
- 
- 
- 
30 
20 
20 
20 
- 
- 
- 
- 
 Sodium 
salicylate 
1.0 
3.0 
5.0 
10.0 
20.00(1.56) 
14.95(1.48) 
14.40(2.36) 
13.85(2.56) 
30.20(0.61) 
17.20(0.72) 
16.95(0.30) 
16.65(0.48) 
0.053 
0.086 
0.093 
0.093 
0.064 
0.113 
0.115 
0.117 
- 
- 
- 
- 
30 
15 
15 
15 
- 
- 
- 
- 
 methylcellulose 1.0 
5.0 
10.0 
20.0 
22.00(1.56) 
25.45(1.48) 
29.24(2.36) 
34.65(2.56) 
50.00(0.55) 
57.20(0.81) 
71.56(0.76) 
96.80(0.88) 
0.032 
0.027 
0.013 
0.006 
0.061 
0.040 
0.028 
0.019 
- 
0.053 
0.042 
0.028 
30 
45 
60 
75 
- 
75 
105 
165 
PEG 
4650 
- 0.0 29.54(2.11) 69.45(1.14) 0.019 0.055 - 60 - 
 Tween 80 1.0 
3.0 
5.0 
10.0 
27.00(1.56) 
23.45(1.48) 
19.58(2.36) 
20.64(2.56) 
64.40(1.32) 
35.25(0.16) 
33.68(0.96) 
36.00(0.48) 
0.023 
0.043 
0.046 
0.041 
0.068 
0.071 
0.075 
0.074 
- 
- 
- 
- 
60 
30 
30 
30 
- 
- 
- 
- 
 Sodium 
salicylate 
1.0 
3.0 
5.0 
10.0 
28.00(1.56) 
23.10(1.48) 
22.56(2.36) 
21.25(2.56) 
53.20(0.64) 
35.52(1.14) 
33.65(0.80) 
32.56(0.16) 
0.026 
0.045 
0.046 
0.049 
0.062 
0.072 
0.075 
0.078 
- 
- 
- 
- 
45 
30 
30 
30 
- 
- 
- 
- 
 methylcellulose 1.0 
5.0 
10.0 
20.0 
31.00(1.56) 
34.68(1.48) 
40.40(2.36) 
46.60(2.56) 
87.90(0.18) 
104.10(0.46) 
123.45(0.44) 
168.00(0.36) 
0.016 
0.015 
0.007 
0.003 
0.036 
0.020 
0.010 
0.007 
- 
0.028 
0.016 
0.012 
60 
60 
75 
90 
- 
90 
135 
240 
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The Kitazawa plot has been used successfully 
to explain the release kinetics of some tablet 
formulations. These formulations were found 
to exhibit monophasic (k1 only) or biphasic (k1 
and k2) release kinetics14, 15, 16. However, it is 
interesting to note that a significant number of 
metronidazole suppositories in the present 
work have exhibited triphasic (k1, k2 and k3) 
release kinetics. This suggests that release 
from these suppositories was more complex 
and involved more processes than release 
from those tablet formulations. This finding 
may help to explain some of the variability 
usually associated with release from 
suppositories2, 7. These findings may also be 
used to manipulate formulation to obtain 
different types of suppositories for different 
purposes. This is because it is sometimes 
preferable to employ sustained-release rather 
than immediate-release suppositories in 
therapy. Sustained-release formulations are 
useful for long term treatment of diseases, 
such as hypertension, acquired immune 
deficiency syndrome – AIDS, anaemia, 
diabetes, and in the treatment of post-
operative  or malignant pain, especially when 
the patient is bed-ridden17,18,19 
 
The biphasic release rate character of some 
of the suppositories may be as a result of the 
release of metronidazole being limited initially 
by the available surface area of the 
suppository, while the second (rapid release) 
phase correspond to the increasing drug 
release from a melting/dissolving suppository 
mass. The triphasic release profile of the 
suppositories containing methylcellulose may 
be attributed to the ability of methylcellulose to 
swell and produce a matrix gel structure at 
certain concentrations15. Thus, such 
suppositories probably maintained their 
integrity for a longer period to afford an initial 
slow release of metronidazole, which 
progressively increased from a slowly 
melting/dissolving mass. 
 
Both Tween 80 and sodium salicylate 
increased the release rates of metronidazole 
from the suppositories. In the case of Tween 
80, this may be due to its ability to improve the 
wettability of the base matrix and thus 
enhance diffusion of the embedded drug 
molecules20. The mechanism by which sodium 
salicylate increased release rate is not clearly 
understood, but could probably be due to the 
high solubility of sodium salicylate21, 22. Rapid 
leaching of the water soluble sodium salicylate 
will be expected to introduce porosity and 
more water sorption into the suppository to 
promote drug release.  
 
It is important to note that optimum 
concentrations of adjuvants can be obtained 
from the present work from the values of most 
of the physical and release properties studied 
(Tables 1 and 2) - setting time, crushing 
strength, disintegration time, t80, k1 and k2. The 
values of these parameters were not generally 
significantly (ρ>0.05) different for PEG 
formulations containing  Tween 80 or sodium 
salicylate (≥  3% w/w), and for witepsol 
formulations containing Tween 80 (>3% w/w) or 
sodium salicylate (>5% w/w). These particular 
concentrations would therefore appear to be 
optimal for Tween 80 and sodium salicylate in 
the different formulations. On the other hand, 
methylcellulose at all concentrations produced 
significant (p<0.05) effects on all the 
parameters evaluated. 
 
The rate of release of metronidazole from 
suppositories containing methylcellulose was 
much slower than from suppositories 
containing Tween 80 and sodium salicylate. 
This was evidenced by the fact that the 
terminal dissolution rate constant (k2) values 
for suppositories containing Tween 80 and 
sodium salicylate were higher than k2 and k3 
values for formulations containing 
methylcellulose (Table 2). The t1 and t2 values 
for relevant methylcellulose formulations were 
also much higher than t1 values for 
formulations containing Tween 80 and sodium 
salicylate. Values of t80 and t2 of up to 168 
minutes (2.8 hrs) and 240 minutes (4.0 hrs) 
respectively (Table 2) were obtained  for 
methylcellulose formulations and these 
suggest that methylcellulose could be useful 
to formulate sustained-release metronidazole 
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suppository formulations, while Tween 80 and 
sodium salicylate can probably be useful only 
for immediate-release suppositories. 
 
CONCLUSION 
The study has shown that different physical 
properties and release rates can be obtained 
for metronidazole suppositories by using 
various bases and formulation adjuvants. 
Optimum concentrations of Tween 80 and 
sodium salicylate can be employed to 
formulate immediate-release suppositories. 
The results also suggest that methylcellulose 
can be used to formulate sustained-release 
metronidazole suppositories. Some insights 
into these inferences on release kinetics of the 
suppositories can be obtained from 
parameters derived from Kitazawa plots, and 
findings from the present work may be 
exploited in designing a rectal delivery system 
of metronidazole. 
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